People: Akebia Therapeutics Inc (AKBA.OQ)
18 Jun 2019
Mr. Michel Dahan serves as Senior Vice President and Chief Business Officer of the Company. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013, most recently as Vice President, Commercial Development and Strategic Planning, and led the global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France) and completed his executive education program (PLD) at Harvard Business School.
|Total Annual Compensation, USD||315,097|
|Restricted Stock Award, USD||400,530|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||561,161|
|Fiscal Year Total, USD||1,276,790|